In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management

por Rifkin, Robert M., Girnius, Saulius K., Noga, Stephen J., Birhiray, Ruemu E., Kambhampati, Suman, Manda, Sudhir, Lyons, Roger M., Yimer, Habte A., Cherepanov, Dasha, Lloyd, Eric, Whidden, Presley, Richter, Joshua
Publicado 2023

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib

por Manda, Sudhir, Yimer, Habte A., Noga, Stephen J., Girnius, Saulius, Yasenchak, Christopher A., Charu, Veena, Lyons, Roger, Aiello, Jack, Bogard, Kimberly, Ferrari, Renda H., Cherepanov, Dasha, Demers, Brittany, Lu, Vickie, Whidden, Presley, Kambhampati, Suman, Birhiray, Ruemu E., Jhangiani, Haresh S., Boccia, Ralph, Rifkin, Robert M.
Publicado 2020